Even as countries around the world have stepped in to require lower priced drugs for their citizens, the United States has been reticent to do so.
As a result, U.S. consumers pay the highest prices in the world for drugs, by a wide margin.
But the impetus for more fundamental reform may come from an unexpected place: America’s obesity epidemic.
Many of us are aware that there is a new class of weight-loss drugs that offer enormous promise in addressing obesity.
But there is far less awareness of the fact that these drugs also introduce an enormous risk to America’s taxpayers.
Organizations:
pharma, Novo Nordisk, Ozempic
Locations:
United States, U.S, Danish